SCHEMBL5049348

SCHEMBL5049348

CC(C)c1ccc(C(=O)NCc2ccc(N(C)C)cc2)cc1

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.72
ALDH1A1 P00352 3/20 0.72
SMN1; SMN2 Q16637 2/20 0.72
KMT2A Q03164 2/20 0.72
MEN1 O00255 1/20 0.72
KDM4E B2RXH2 1/20 0.72
HTT P42858 1/20 0.72
NPC1 O15118 2/20 0.67
CA2 P00918 1/20 0.64
HDAC1 Q13547 3/20 0.60
HDAC6 Q9UBN7 2/20 0.60
HDAC4 P56524 2/20 0.60
HDAC3 O15379 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60
HDAC5 Q9UQL6 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21091969 0.89 ALDH1A1 (0.88) ALDH1A1SMN1; SMN2KDM4EHTTCA2
Hydrochloric Acid SCHEMBL28938255 0.88 ALDH1A1 (0.85) ALDH1A1SMN1; SMN2KDM4EHTTCA2
SCHEMBL2701623 0.85 ALDH1A1 (0.76) RAB9AALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL30828559 0.85 ALDH1A1 (0.80) RAB9AALDH1A1KDM4EHTTNPC1
SCHEMBL3919500 0.84 ALDH1A1 (0.78) ALDH1A1SMN1; SMN2KDM4EHTTCA2
SCHEMBL4737519 0.82 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2KMT2AKDM4EHTT
SCHEMBL2701620 0.82 ALDH1A1 (0.76) ALDH1A1SMN1; SMN2KDM4EHTTCA2
SCHEMBL24934740 0.82 RAB9A (0.76) RAB9AALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL18232439 0.82 RAB9A (0.76) RAB9AALDH1A1SMN1; SMN2KMT2AMEN1
SCHEMBL10099559 0.82 SMN1; SMN2 (0.76) RAB9AALDH1A1SMN1; SMN2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8071810-B2 3-(3-Amino-2,6-diisopropyl-phenyl)-1-(4-isopropyl-phenyl)-1-(4-methoxy-benzyl)-urea; autoimmune disorders; inflammation JERINI AG (DE) 2011-12-06 US disclosed
US-20080220003-A1 C5a Receptor Antagonists JERINI AG (DE) 2008-09-11 US disclosed
US-7291621-B2 Substituted biaryl amides C5a receptor modulators NEUROGEN CORPORATION (US) 2007-11-06 US disclosed
EP-1739078-A1 Antagonists of C5a-receptor Jerini AG (DE) 2007-01-03 EP disclosed
US-7148225-B2 Substituted biaryl amides as C5A receptor modulators NEUROGEN CORPORATION (US) 2006-12-12 US disclosed
US-20060178414-A1 Substituted biaryl amides as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2006-08-10 US disclosed
EP-1487796-A4 SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS NEUROGEN CORP (US) 2005-11-16 EP disclosed
US-20050096358-A1 Substituted biaryl amides as C5A receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2005-05-05 US disclosed
US-6858637-B2 Treating rheumatoid arthritis, psoriasis, cardiovascular disease, reperfusion injury, and bronchial asthma; e.g., 2-Methoxynaphthalene-1-carboxylic acid benzyl-indan-2-yl-amide NEUROGEN CORPORATION (US) 2005-02-22 US disclosed
EP-1487796-A1 SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2004-12-22 EP disclosed
US-20040048913-A1 Substituted biaryl amides as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2004-03-11 US disclosed
WO-2003082826-A1 SUBSTITUTED BIARYL AMIDES AS C5A RECEPTOR MODULATORS NEUROGEN CORPORATION (US) 2003-10-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040048913-A1 Substituted biaryl amides as C5a receptor modulators C5AR1, C5AR2, C3AR1 RAB9A 1382/4885ALDH1A1 1494/4885SMN1; SMN2 3169/4885
US-20050096358-A1 Substituted biaryl amides as C5A receptor modulators C5AR1, C5AR2, C3AR1 RAB9A 1353/4885ALDH1A1 1680/4885SMN1; SMN2 3354/4885
US-20060178414-A1 Substituted biaryl amides as C5a receptor modulators C5AR1, C5AR2, C3AR1 RAB9A 1353/4885ALDH1A1 1680/4885SMN1; SMN2 3354/4885
US-20080220003-A1 C5a Receptor Antagonists C3AR1, C5AR2, C5AR1 RAB9A 2366/4885ALDH1A1 3680/4885SMN1; SMN2 4617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.